

Designing Peptide Inhibitors to Prevent Amyloid Beta Aggregation

Krishnareddygar, Saanvi (School: Lewis & Clark High School)

In Alzheimer's disease, a progressive neurodegenerative disease, a key pathological feature of the is the accumulation of amyloid- β peptides in the brain, which aggregate to form plaques that disrupt neuronal function and contribute to cognitive decline. Current therapeutic strategies have largely focused on small molecule inhibitors; however, these compounds often struggle to effectively bind the large protein interfaces involved in amyloid aggregation. Peptide inhibitors offer a promising alternative due to their higher specificity and ability to interact with larger binding surfaces on target proteins. In this project, I aimed to identify the potential of short peptide inhibitors to bind amyloid- β and disrupt its aggregation process. Peptides were designed and structurally modeled using UCSF ChimeraX. The amyloid- β structure was obtained from the Protein Data Bank and prepared through hydrogen addition and energy minimization. Protein-peptide docking simulations were then conducted using the HDock to predict binding interactions between amyloid- β and candidate peptide inhibitors. Docking scores and predicted binding interfaces were analyzed to identify peptides with the strongest affinity for aggregation-prone regions of amyloid- β . The results of this study aim to identify peptide sequences with strong predicted binding to amyloid- β that may inhibit fibril formation. By using computational structural biology tools to screen potential inhibitors, this research demonstrates an accessible method for early-stage therapeutic discovery and contributes to ongoing efforts to develop treatments targeting protein aggregation in neurodegenerative diseases.

Awards Won:

